Deltex Medical Group Plc (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about its new monitor sales in the US and UK. Ewan explains how the orders came about, the focus on US markets, his thoughts on the NHS and UK healthcare markets and his thoughts for the company in 2017.
Ewan has been Chief Executive since 2009. Ewan joined the Company as Finance Director in 2001 and was Managing Director of the UK subsidiary from 2005. He has served on a number of Association of British Healthcare Industries committees including joint industry/government working groups. Ewan’s background is in corporate finance.
Deltex Medical Group Plc is a British manufacturer of Fluid Management devices, which include the CardioQ-ODM and CardioQ-ODM+. Both manufacturing and Head Office are based in Chichester, West Sussex with subsidiaries in the USA, Canada and Spain. The goal is to make oesophageal Doppler monitoring (ODM) a standard of care for patients. They believe that, in most modern health systems, it is essential to have a robust evidence base of both clinical benefit and cost effectiveness in order to achieve system-wide adoption of a new medical technology. The company is one of the very first medical technology companies to have completed the investment necessary to build such an evidence base. As a result, use of ODM during surgery has the proven potential to deliver both clinical and economic benefits that are material at patient, hospital and system level. The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide and there are already over 3,000 CardioQ-ODM systems in use in hospitals globally. Distribution arrangements are in place in over 30 countries.
